Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Director Ashley Keating Resigns; Dani Zander Joins Board July 1

Neutral Impact 2 of 5 leadership Written later

Medpace director Ashley M. Keating resigned from the Board effective June 30, 2024, stating no disagreement with the company. The Board appointed Dr. Dani S. Zander to fill the resulting Class III vacancy effective July 1, 2024, and to the Nominating and Governance Committee.

Key points

  • Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies or practices cited.
  • Dr. Dani S. Zander was elected to the Class III vacancy effective July 1, 2024, serving until the 2025 Annual Meeting of Stockholders.
  • Dr. Zander joined the Nominating and Governance Committee effective July 1, 2024.
  • Dr. Zander received a director equity award of an option to purchase 824 shares at the July 1, 2024 closing price, with a seven-year term.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECJul 3, 2024, 4:37 PM ET
Accession number0001193125-24-175077

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 03, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.